Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (NexavarÂ®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma.

The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day
Uveal Melanoma
DRUG: Sorafenib at a dose of 800 mg / day
non-tumor progression rate, with sorafenib at a dose of 800 mg / day, 24 weeks after initiation of treatment
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma.

The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day